MXPA05009574A - Derivados de 8'-piridinil- dihidrospiro -[cicloalquil]- pirimido[1, 2a] pirimidin-6- ona y y 8'-pirimidinil- dihidrospiro -[cicloalquil]- pirimido [1, 2a]pirimidin-6 -ona substituidos y su uso contra enfermedades neurodegenerativas. - Google Patents
Derivados de 8'-piridinil- dihidrospiro -[cicloalquil]- pirimido[1, 2a] pirimidin-6- ona y y 8'-pirimidinil- dihidrospiro -[cicloalquil]- pirimido [1, 2a]pirimidin-6 -ona substituidos y su uso contra enfermedades neurodegenerativas.Info
- Publication number
- MXPA05009574A MXPA05009574A MXPA05009574A MXPA05009574A MXPA05009574A MX PA05009574 A MXPA05009574 A MX PA05009574A MX PA05009574 A MXPA05009574 A MX PA05009574A MX PA05009574 A MXPA05009574 A MX PA05009574A MX PA05009574 A MXPA05009574 A MX PA05009574A
- Authority
- MX
- Mexico
- Prior art keywords
- dihydrospiro
- cycloalkyl
- pyrimido
- pyrimidin
- ring
- Prior art date
Links
- 125000000753 cycloalkyl group Chemical group 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 abstract 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03290569A EP1454909B1 (en) | 2003-03-07 | 2003-03-07 | 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases |
| PCT/EP2004/003051 WO2004078760A1 (en) | 2003-03-07 | 2004-03-05 | SUBSTITUTED 8'-PYRIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE AND 8'-PYRIMIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05009574A true MXPA05009574A (es) | 2006-05-19 |
Family
ID=32799103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05009574A MXPA05009574A (es) | 2003-03-07 | 2004-03-05 | Derivados de 8'-piridinil- dihidrospiro -[cicloalquil]- pirimido[1, 2a] pirimidin-6- ona y y 8'-pirimidinil- dihidrospiro -[cicloalquil]- pirimido [1, 2a]pirimidin-6 -ona substituidos y su uso contra enfermedades neurodegenerativas. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7294632B2 (enExample) |
| EP (2) | EP1454909B1 (enExample) |
| JP (1) | JP4639182B2 (enExample) |
| KR (1) | KR101069984B1 (enExample) |
| CN (1) | CN100463908C (enExample) |
| AR (1) | AR043485A1 (enExample) |
| AT (1) | ATE469153T1 (enExample) |
| AU (1) | AU2004218250B2 (enExample) |
| BR (1) | BRPI0408189A (enExample) |
| CA (1) | CA2516937C (enExample) |
| CY (1) | CY1111057T1 (enExample) |
| DE (1) | DE602004027354D1 (enExample) |
| DK (1) | DK1603915T3 (enExample) |
| EA (1) | EA008172B1 (enExample) |
| ES (1) | ES2346311T3 (enExample) |
| IL (1) | IL170461A (enExample) |
| MX (1) | MXPA05009574A (enExample) |
| NO (1) | NO20054140L (enExample) |
| NZ (1) | NZ542135A (enExample) |
| PL (1) | PL1603915T3 (enExample) |
| PT (1) | PT1603915E (enExample) |
| SI (1) | SI1603915T1 (enExample) |
| TW (1) | TWI320785B (enExample) |
| WO (1) | WO2004078760A1 (enExample) |
| ZA (1) | ZA200507107B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080025079A (ko) | 2005-06-14 | 2008-03-19 | 쉐링 코포레이션 | 아스파르틸 프로테아제 억제제 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| EP1992620A1 (en) * | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases |
| EP1992625A1 (en) * | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Arylamide pyrimidone compounds |
| EP1992621A1 (en) * | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases |
| EP1992624A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide pyrimidone compounds |
| EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| EP2138494A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
| EP2138485A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
| EP2138495A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives |
| EP2138498A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted tricyclic derivatives against neurodegenerative diseases |
| EP2138488A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| EP2138492A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidin-4-one derivatives |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| SI2448940T1 (sl) | 2009-07-02 | 2014-10-30 | Sanofi | Derivati 6,7,8,9-tetrahidro-pirimido(1,2-a)pirimidin-4-ona, njihova priprava in njihova farmacevtska uporaba |
| WO2012085244A1 (fr) | 2010-12-23 | 2012-06-28 | Sanofi | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| FR2992316A1 (fr) | 2012-06-22 | 2013-12-27 | Sanofi Sa | Derives de pyrimidinones, leur preparation et leur application en therapeutique |
| WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2812636A1 (fr) * | 2000-08-02 | 2002-02-08 | Novapharme | Nouveaux derives 2-phenyl imidazo[1.2-a]pyrimidin-5-ones et 2-phenyl 2,3-dihydro imidazo[1,2-a]pyrimidin-5-ones |
| EP1184385A1 (en) * | 2000-09-01 | 2002-03-06 | Sanofi-Synthelabo | 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives |
| ATE269333T1 (de) * | 2000-09-01 | 2004-07-15 | Sanofi Synthelabo | 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-on- und 7-pyridinyl-2,3- dihydroimidazo(1,2-a)pyrimidin-5 1honderivate |
| EP1184383A1 (en) * | 2000-09-01 | 2002-03-06 | Sanofi-Synthelabo | 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives |
| EP1295884A1 (en) * | 2001-09-21 | 2003-03-26 | Sanofi-Synthelabo | 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives |
| KR100868840B1 (ko) * | 2001-09-21 | 2008-11-14 | 사노피-아벤티스 | 신경퇴행성 장애를 위한 치환된2-피리미디닐-6,7,8,9-테트라히드로피리미도[1,2-ａ]피리미딘-4-온 및7-피리미디닐-2,3-디히드로이미다조[1,2-ａ]피리미딘-5(1ｈ)온 유도체 |
| DE60227718D1 (de) * | 2001-09-21 | 2008-08-28 | Sanofi Aventis | Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen |
| EP1295885A1 (en) * | 2001-09-21 | 2003-03-26 | Sanofi-Synthelabo | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives |
-
2003
- 2003-03-07 EP EP03290569A patent/EP1454909B1/en not_active Expired - Lifetime
-
2004
- 2004-03-05 DE DE602004027354T patent/DE602004027354D1/de not_active Expired - Lifetime
- 2004-03-05 CN CNB2004800109973A patent/CN100463908C/zh not_active Expired - Fee Related
- 2004-03-05 TW TW093105914A patent/TWI320785B/zh not_active IP Right Cessation
- 2004-03-05 DK DK04717643.3T patent/DK1603915T3/da active
- 2004-03-05 AT AT04717643T patent/ATE469153T1/de active
- 2004-03-05 WO PCT/EP2004/003051 patent/WO2004078760A1/en not_active Ceased
- 2004-03-05 PL PL04717643T patent/PL1603915T3/pl unknown
- 2004-03-05 CA CA2516937A patent/CA2516937C/en not_active Expired - Fee Related
- 2004-03-05 ZA ZA200507107A patent/ZA200507107B/en unknown
- 2004-03-05 AU AU2004218250A patent/AU2004218250B2/en not_active Ceased
- 2004-03-05 BR BRPI0408189-7A patent/BRPI0408189A/pt not_active IP Right Cessation
- 2004-03-05 AR ARP040100694A patent/AR043485A1/es not_active Application Discontinuation
- 2004-03-05 PT PT04717643T patent/PT1603915E/pt unknown
- 2004-03-05 EP EP04717643A patent/EP1603915B1/en not_active Expired - Lifetime
- 2004-03-05 JP JP2006504813A patent/JP4639182B2/ja not_active Expired - Fee Related
- 2004-03-05 NZ NZ542135A patent/NZ542135A/en not_active IP Right Cessation
- 2004-03-05 MX MXPA05009574A patent/MXPA05009574A/es active IP Right Grant
- 2004-03-05 ES ES04717643T patent/ES2346311T3/es not_active Expired - Lifetime
- 2004-03-05 SI SI200431465T patent/SI1603915T1/sl unknown
- 2004-03-05 EA EA200501241A patent/EA008172B1/ru not_active IP Right Cessation
-
2005
- 2005-08-23 IL IL170461A patent/IL170461A/en not_active IP Right Cessation
- 2005-09-06 KR KR1020057016622A patent/KR101069984B1/ko not_active Expired - Fee Related
- 2005-09-06 NO NO20054140A patent/NO20054140L/no not_active Application Discontinuation
- 2005-09-07 US US11/220,999 patent/US7294632B2/en not_active Expired - Fee Related
-
2007
- 2007-10-02 US US11/866,142 patent/US7507743B2/en not_active Expired - Fee Related
-
2010
- 2010-08-17 CY CY20101100761T patent/CY1111057T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05009574A (es) | Derivados de 8'-piridinil- dihidrospiro -[cicloalquil]- pirimido[1, 2a] pirimidin-6- ona y y 8'-pirimidinil- dihidrospiro -[cicloalquil]- pirimido [1, 2a]pirimidin-6 -ona substituidos y su uso contra enfermedades neurodegenerativas. | |
| TW200504070A (en) | 8-substituted-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | |
| EA200601192A1 (ru) | ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 8'-ПИРИ(МИ)ДИНИЛДИГИДРОСПИРО[ЦИКЛОАЛКИЛАМИН]ПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА | |
| MXPA05010112A (es) | Derivados 8-perfluoroalquil-6, 7, 8, 9-tetrahidropirimido [1,2-a] pirimidin-4 -ona substituidos. | |
| MX2009004884A (es) | Derivados 8-piperidinil-2-piridinil-pirimido [1,2-a] pirimidin-6-ona y 8-piperidinil-2-pirimidinil-pirimido [1,2-a] pirimidin-6-ona sustuidos. | |
| MX2009006947A (es) | Derivados de pirimidona 6-heterociclica 2-sustituida. | |
| WO2005092895A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists | |
| EA200600196A1 (ru) | Производные замещенного 2-пиримидинил-6,7,8,9-тетрагидропиримидо[1,2-a]пиримидин-4-она и 7-пиримидинил-2,3-дигидроимидазо[1,2-a]пиримидин-5(1н) она для нейродегенеративных нарушений | |
| WO2007110627A3 (en) | 3,7-diamino-10h-phenothiazine salts and their use | |
| MX2010005753A (es) | Derivados de isoxazolo-pirazina. | |
| EP1396493A4 (en) | HETEROCYCLIC COMPOUNDS | |
| WO2007057790A3 (en) | Substituted bicyclic pyrimidone derivatives | |
| CA2501799A1 (en) | Pyrazole compounds for treatment of neurodegenerative disorders | |
| EA200400936A1 (ru) | ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2-ПИРИДИНИЛ- И 2-ПИРИМИДИНИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА | |
| WO2003027116A3 (en) | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives | |
| TW200626573A (en) | Pyrimidone compound | |
| SG161217A1 (en) | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | |
| WO2008136377A1 (ja) | 二環式複素環化合物 | |
| ATE402707T1 (de) | Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen | |
| MX2010002765A (es) | Derivado de 6-pirimidinil-pirimid-4-ona. | |
| TH69758A (th) | อนุพันธ์สับสติติวท์ 8-เปอร์ฟลูออโรอัลคิล-6,7,8,9-เตตราไฮโดรไพริมิโด[1,2-a]ไพริมิดิน-4-โอน | |
| TH74460A (th) | อนุพันธ์ของ 8'-พิริ(มิ)ดินิล-ไดไฮโดรสไปโร-[ไซโคลอัลคิลามีน]-พิริมิโด[1,2-a]พิริมิดิน-6-โอน ที่ถูกแทนที่ | |
| TH82135A (th) | อนุพันธ์ซับสทิทิวเทด 8'-ไพริคินิล-ไดไฮโดรสไพโร-[ไซโคลแอลคิล]-ไพริมิโด[1,2-a]ไพริมิดิน-6-โอน และ 8'-ไพริมิดินิล-ไดไฮโดรสไพโร-[ไซโคลแอลคิล]-ไพริมิโด[1,2-a]ไพริมิดิน-6-โอน | |
| TH70366A (th) | อนุพันธ์ 8-สับสติติวท์-6,7,8,9-เตตราไฮโดรไพริมิโด [1,2-a] ไพริมิดิน-4-โอน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |